All In Biotech

Drug Trial Radar · NCT05303636

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density (BMD) in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

1,536

Actual

Start

Mar 28, 2022

Primary completion

Dec 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Insud PharmaIndustry
Sponsor type
Industry
Collaborators
Chemo Research
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Factorial
Masking
None
Primary purpose
Screening
FDA-regulated drug
Yes
Who can join
Female only, from 14 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in comparison to non-hormonal contraceptive methods. Secondary objectives include further evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on BMD and bone turnover after 12 months (13 medication cycles) in comparison to non-hormonal contraceptive methods and assessing the general safety and tolerability of LF111 and DRSP 3.5 mg chewable tablets in comparison to non-hormonal contraceptive methods. Exploratory objectives include evaluating the impact of LF111 and DRSP 3.5 mg chewable tablets on body fat and lean mass after 12 months (13 medication cycles) of investigation.

Conditions

  • Change in Bone Mineral Density
  • Bone Loss

Interventions

  • drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tabletDrug

    Drospirenone 4 mg tablet (LF1111) orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28 (available in USA and Europe) or drospirenone 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (available in USA only).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Mean absolute change in lumbar spine (L1-L4) Z-score in adolescentsTime frame: Baseline to 12 months
  2. Cohort 2: Mean percentage change in lumbar spine (L1-L4) BMD in adultsTime frame: Baseline to 12 months

Locations

37 sites in 3 countries. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus

    Aurora, Colorado

  • Encore Medical Research of Boynton Beach LLC

    Boynton Beach, Florida

  • Advanced Clinical Research Network

    Coral Gables, Florida

  • BioMD Research

    Coral Gables, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • Health Care Family Rehab & Research Center

    Hialeah, Florida

  • Vital Pharma Research

    Hialeah, Florida

  • Encore Medical Research, LLC

    Hollywood, Florida

  • Cornerstone Research Institute

    Longwood, Florida

  • D&H National Research Centers

    Miami, Florida

  • Miami Clinical Research

    Miami, Florida

  • Felicidad Medical Research, LLC

    Miami, Florida

  • New Age Medical Research Corporation

    Miami, Florida

  • KM International Research Operation LLC

    Saint Cloud, Florida

  • Florida Pharmaceutical Research and Associates, Inc.

    South Miami, Florida

  • Encore Medical Research of Weston LLC

    Weston, Florida

  • Clinical Trials Management, LLC - Southshore

    Metairie, Louisiana

  • University of Michigan C.S. Mott Children's Hospital

    Ann Arbor, Michigan

  • Meridian Clinical Research

    Norfolk, Nebraska

  • Lillestol Research LLC

    Fargo, North Dakota

  • OB/GYN Associates of Erie

    Erie, Pennsylvania

  • Signature Gyn Services

    Fort Worth, Texas

  • TMC Life Research, Inc.

    Houston, Texas

  • Tidewater Clinical Research, Inc.

    Norfolk, Virginia

  • Children's Hospital of the King's Daughters

    Norfolk, Virginia

  • Seattle Clinical Research Center

    Seattle, Washington

  • Lékárna Devetsil JST s.r.o.

    Slovany, Czechia

  • Lékárna U Zvonice

    Vysoké Mýto, Czechia

  • Centrum Bocian Sp Z O. O. Spólka Komandytowa

    Bialystok, Poland

  • Centrum Bocian Sp z o.o. Sp.

    Katowice, Poland

  • GynCentrum Sp. z o.o.

    Katowice, Poland

  • Vita Longa Sp. z o.o.

    Katowice, Poland

  • Centrum Medyczne Linden

    Krakow, Poland

  • Grazyna Bogutyn Medico Praktyka Lekarska

    Krakow, Poland

  • CM Medyceusz, Apteka szpitalna

    Lodz, Poland

  • Klinika Leczenia Nieplodnosci, Ginekologii i Poloznictwa Bocian

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.